
|Articles|December 17, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Treatment of Melanoma With Emerging Targeted Therapies
Author(s)Georgina Long, BSc, PhD, MBBS, FRACP
Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses the treatment of melanoma with emerging targeted therapies.
Advertisement
Articles in this issue
about 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasabout 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaabout 12 years ago
Advances in Metastatic Melanomaabout 12 years ago
Targeted Therapies in Basal Cell Carcinomaabout 12 years ago
The Outlook for BRAF Inhibitors in MelanomaAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















